Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | HPN | P05981 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24153004 | 1.00 | PIK3CD (0.37) | PIK3CDPKMSMN1; SMN2MMP1MMP2 | |
| SCHEMBL10166041 | 0.87 | ALOX5 (0.32) | SMN1; SMN2MMP1MMP2MMP3MMP9 | |
| SCHEMBL19400738 | 0.85 | MMP2 (0.38) | SMN1; SMN2MMP1MMP2MMP3MMP9 | |
| SCHEMBL24311892 | 0.85 | MMP2 (0.34) | SMN1; SMN2MMP1MMP2MMP3MMP9 | |
| SCHEMBL14511428 | 0.85 | MMP2 (0.38) | SMN1; SMN2MMP1MMP2MMP3MMP9 | |
| SCHEMBL14511415 | 0.83 | MMP2 (0.41) | SMN1; SMN2MMP1MMP2MMP3MMP9 | |
| SCHEMBL13792257 | 0.83 | MMP2 (0.41) | SMN1; SMN2MMP1MMP2MMP3MMP9 | |
| SCHEMBL24312143 | 0.79 | PIK3CD (0.35) | PIK3CDSMN1; SMN2MMP1MMP2MMP3 | |
| SCHEMBL888728 | 0.78 | MAPK1 (0.38) | PIK3CDPKMSMN1; SMN2MMP1MMP2 | |
| SCHEMBL825037 | 0.78 | MAPK1 (0.38) | PIK3CDPKMSMN1; SMN2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | PIK3CD 3584/4885PKM 1721/4885SMN1; SMN2 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.